Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 3.5 Amended and Restated Certificate of Incorporation of Oruka Therapeutics, Inc
- 3.6 Bylaws of Oruka Therapeutics, Inc, As Currently In Effect
- 4.3 Investor Rights Agreement, Dated March 6, 2024, by and Among Oruka Therapeutics, Inc. and Certain Parties Thereto
- 10.40 Oruka Therapeutics, Inc. 2024 Equity Incentive Plan
- 10.41 Form of Restricted Stock Notice and Restricted Stock Purchase Agreement of Oruka Therapeutics, Inc
- 10.42 Form of Stock Option Agreement Under Oruka Therapeutics, Inc. 2024 Equity Incentive Plan
- 10.43 Amended and Restated Director Offer Letter, Dated March 22, 2024, Between Oruka Therapeutics, Inc. and Samarth Kulkarni
- 10.44 Director Offer Letter, Dated April 24, 2024, Between Oruka Therapeutics, Inc. and Kristine Ball
- 10.45 Form of Indemnification Agreement Between Oruka Therapeutics, Inc. and Its Directors and Officers
- 10.46 Amended and Restated Employment Offer Letter, Dated February 14, 2024, by and Between Oruka Therapeutics, Inc. and Lawrence Klein
- 10.47 Amended and Restated Employment Offer Letter, Dated March 11, 2024, by and Between Oruka Therapeutics, Inc. and Arjun Agarwal
- 10.48 Amended and Restated Employment Offer Letter, Dated March 15, 2024, by and Between Oruka Therapeutics, Inc. and Joana Goncalves
- 10.49 Amended and Restated Employment Offer Letter, Dated April 12, 2024, by and Between Oruka Therapeutics, Inc. and Paul Quinlan
- 21.1 List of Subsidiaries of Arca Biopharma, Inc
- 23.1 Consent of KPMG LLP, Independent Registered Public Accounting Firm of Arca Biopharma, Inc
- 23.2 Consent of Pricewaterhousecoopers LLP, Independent Registered Public Accounting Firm of Oruka Therapeutics, Inc
- 99.5 Consent of Lucid Capital Markets, LLC
- 99.6 Consent of Lawrence Klein to Serve As a Director of Arca Biopharma, Inc., to Be Renamed Oruka Therapeutics, Inc
- 99.7 Consent of Kristine Ball to Serve As a Director of Arca Biopharma, Inc., to Be Renamed Oruka Therapeutics, Inc
- 99.8 Consent of Carl Dambkowski to Serve As a Director of Arca Biopharma, Inc., to Be Renamed Oruka Therapeutics, Inc
- 99.9 Consent of Peter Harwin to Serve As a Director of Arca Biopharma, Inc., to Be Renamed Oruka Therapeutics, Inc
- 99.10 Consent of Samarth Kulkarni to Serve As a Director of Arca Biopharma, Inc., to Be Renamed Oruka Therapeutics, Inc
- 99.11 Consent of Cameron Turtle to Serve As a Director of Arca Biopharma, Inc., to Be Renamed Oruka Therapeutics, Inc
- EX-FILING FEES Filing Fee Table
- Download Excel data file
- View Excel data file
Associated filings
- 18 Jun 24 S-4/A Registration of securities issued in business combination transactions (amended)
-
13 May 24 S-4 Registration of securities issued in business combination transactions
ABIO similar filings
- 18 Jun 24 Registration of securities issued in business combination transactions (amended)
- 13 May 24 Registration of securities issued in business combination transactions
- 24 Nov 08 Registration of securities issued in business combination transactions (amended)
- 30 Oct 08 Registration of securities issued in business combination transactions
- 13 Dec 02 Registration of securities issued in business combination transactions (amended)
Filing view
External links
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the use in this Registration Statement on Form S-4 of ARCA biopharma, Inc. of our report dated May 13, 2024 relating to the financial statement of Oruka Therapeutics, Inc., which appears in this Registration Statement. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
May 13, 2024